Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP known ✓ | O00591 | 2/20 | 0.37 |
| ▸ | GABRD known ✓ | O14764 | 2/20 | 0.37 |
| ▸ | GABRA1 known ✓ | P14867 | 2/20 | 0.37 |
| ▸ | GABRB1 known ✓ | P18505 | 2/20 | 0.37 |
| ▸ | GABRG2 known ✓ | P18507 | 2/20 | 0.37 |
| ▸ | GABRB3 known ✓ | P28472 | 2/20 | 0.37 |
| ▸ | GABRA5 known ✓ | P31644 | 2/20 | 0.37 |
| ▸ | GABRA3 known ✓ | P34903 | 2/20 | 0.37 |
| ▸ | GABRA2 known ✓ | P47869 | 2/20 | 0.37 |
| ▸ | GABRB2 known ✓ | P47870 | 2/20 | 0.37 |
| ▸ | GABRA4 known ✓ | P48169 | 2/20 | 0.37 |
| ▸ | GABRE known ✓ | P78334 | 2/20 | 0.37 |
| ▸ | GABRA6 known ✓ | Q16445 | 2/20 | 0.37 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 2/20 | 0.37 |
| ▸ | GABRG3 known ✓ | Q99928 | 2/20 | 0.37 |
| ▸ | GABRQ known ✓ | Q9UN88 | 2/20 | 0.37 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9076573 | 1.00 | ALOX15 (0.41) | ALOX15PIN1ALDH1A1MEN1NPC1 | |
| SCHEMBL1074665 | 0.98 | ALOX15 (0.42) | ALOX15PIN1ALDH1A1MEN1NPC1 | |
| SCHEMBL1074666 | 0.98 | ALOX15 (0.42) | ALOX15PIN1ALDH1A1MEN1NPC1 | |
| Hydrochloric Acid SCHEMBL3024512 | 0.83 | MGAM (0.46) | ALOX15PIN1ALDH1A1KMT2ALMNA | |
| Hydrochloric Acid SCHEMBL21247031 | 0.83 | ALOX15 (0.46) | ALOX15PIN1ALDH1A1MEN1NPC1 | |
| Hydrochloric Acid SCHEMBL3024514 | 0.83 | MGAM (0.46) | ALOX15PIN1ALDH1A1KMT2ALMNA | |
| Hydrochloric Acid SCHEMBL22615898 | 0.83 | ALDH1A1 (0.42) | ALOX15PIN1ALDH1A1MEN1NPC1 | |
| Hydrochloric Acid SCHEMBL21247032 | 0.83 | ALOX15 (0.46) | ALOX15PIN1ALDH1A1MEN1NPC1 | |
| Hydrochloric Acid SCHEMBL29401282 | 0.83 | MGAM (0.46) | ALOX15PIN1ALDH1A1KMT2ALMNA | |
| SCHEMBL16098107 | 0.82 | NOD1 (0.43) | ALDH1A1NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120041156-A | Kerosene phase change material with solid-liquid thixotropic reversible conversion performance | 中国科学院化学研究所 | 2025-05-27 | — | — | CN | disclosed |
| CN-108017555-B | Beta-hydroxybutyryl-amino acid compound and preparation method and application thereof | 郑州海斯威生物技术有限公司 | 2021-03-26 | — | — | CN | disclosed |
| WO-2019104851-A4 | BETA-HYDROXYBUTYRYL-AMINO ACID COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 刘成 | 2019-08-15 | — | — | WO | disclosed |
| CN-106588682-A | New preparation method of ethyl aspartate hydrochloride | 张家港市华昌药业有限公司 | 2017-04-26 | — | — | CN | disclosed |
| CN-106588682-A | New preparation method of ethyl aspartate hydrochloride | 张家港市华昌药业有限公司 | 2017-04-26 | — | — | CN | disclosed |
| US-9163021-B2 | Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors | PFIZER LIMITED (GB) | 2015-10-20 | — | — | US | disclosed |
| US-20150246912-A1 | Pyrrolo[3,2-C]Pyridine Tropomyosin-Related Kinase Inhibitors | PFIZER LIMITED (GB) | 2015-09-03 | — | — | US | disclosed |
| EP-2912036-A1 | PYRROLO[3,2-C]PYRIDINE TROPOMYOSIN-RELATED KINASE INHIBITORS | Pfizer Limited (GB) | 2015-09-02 | — | — | EP | disclosed |
| WO-2014053968-A1 | PYRROLO[3,2-C]PYRIDINE TROPOMYOSIN-RELATED KINASE INHIBITORS | PFIZER LIMITED (GB) | 2014-04-10 | — | — | WO | disclosed |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | NOVO NORDISK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
| US-20060069013-A1 | Pharmaceutical preparations comprising acid-stabilised insulin | NOVO NORDISK A/S (DK) | 2006-03-30 | — | — | US | disclosed |
| WO-2006005683-A1 | PHAMACEUTICAL PREPARATIONS COMPRISING INSULIN | NOVO NORDISK A/S (DK) | 2006-01-19 | — | — | WO | disclosed |
| EP-1610812-A1 | PHARMACEUTICAL PREPARATIONS COMPRISING ACID-STABILISED INSULIN | NOVO NORDISK A/S (DK) | 2006-01-04 | — | — | EP | disclosed |
| EP-1605967-A1 | NOVEL NPH INSULIN PREPARATIONS | NOVO NORDISK A/S (DK) | 2005-12-21 | — | — | EP | disclosed |
| EP-1585541-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER | NOVO NORDISK A/S (DK) | 2005-10-19 | — | — | EP | disclosed |
| US-20050065066-A1 | comprising insulin and novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer; physical and chemical stability | NOVO NORDISK A/S (DK) | 2005-03-24 | — | — | US | disclosed |
| WO-2004080481-A1 | NOVEL NPH INSULIN PREPARATIONS | NOVO NORDISK A/S (DK) | 2004-09-23 | — | — | WO | disclosed |
| WO-2004080480-A1 | PHARMACEUTICAL PREPARATIONS COMPRISING ACID-STABILISED INSULIN | NOVO NORDISK A/S (DK) | 2004-09-23 | — | — | WO | disclosed |
| WO-2004056347-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER | NOVO NORDISK A/S (DK) | 2004-07-08 | — | — | WO | disclosed |
| US-4325954-A | ANTIDEPRESSANTS | LABORATOIRES JACQUES LOGEAIS (FR) | 1982-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150246912-A1 | Pyrrolo[3,2-C]Pyridine Tropomyosin-Related Kinase Inhibitors | MUSK, TPM3, DMPK | GABRP 814/4885GABRD 1313/4885GABRA1 1848/4885 |
| US-20060069013-A1 | Pharmaceutical preparations comprising acid-stabilised insulin | IAPP, GPR119, INSR | GABRP 664/4885GABRD 2122/4885GABRA1 2252/4885 |
| US-20050065066-A1 | comprising insulin and novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer; physical and chemical stability | IAPP, IRS1, INSR | GABRP 1129/4885GABRD 3178/4885GABRA1 3355/4885 |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | IAPP, IRS1, HBB | GABRP 184/4885GABRD 776/4885GABRA1 955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.